Turnstone Biologics Corp. financial data

Symbol
TSBX on Nasdaq
Location
9310 Athena Circle, Suite 300, La Jolla, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 8, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 376 % -46.5%
Debt-to-equity 34.1 % +90.6%
Return On Equity -172 % -103%
Return On Assets -128 % -78.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23.1M shares +0.05%
Common Stock, Shares, Outstanding 23.1M shares +0.05%
Entity Public Float 44.9M USD
Common Stock, Value, Issued 23K USD 0%
Weighted Average Number of Shares Outstanding, Basic 23.1M shares +0.45%
Weighted Average Number of Shares Outstanding, Diluted 23.1M shares +0.45%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 19.3M USD
Research and Development Expense 44.7M USD -26.3%
General and Administrative Expense 17.4M USD -5.59%
Operating Income (Loss) -44.5M USD +44.1%
Nonoperating Income (Expense) -2.7M USD -158%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -47.2M USD +37%
Income Tax Expense (Benefit) 33K USD +500%
Net Income (Loss) Attributable to Parent -47.2M USD +36.8%
Earnings Per Share, Basic -2 USD/shares +73.9%
Earnings Per Share, Diluted -2 USD/shares +73.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 16.7M USD -4.1%
Cash, Cash Equivalents, and Short-term Investments 77.8M USD
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Other Assets, Current 1.57M USD -33.1%
Assets, Current 21.1M USD -69.1%
Property, Plant and Equipment, Net 602K USD -89.2%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 21.1M USD -72.5%
Accounts Payable, Current 2.69M USD +80.8%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 6.35M USD -59.4%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 6.35M USD -63%
Accumulated Other Comprehensive Income (Loss), Net of Tax -202K USD +10.6%
Retained Earnings (Accumulated Deficit) -265M USD -21.7%
Stockholders' Equity Attributable to Parent 14.8M USD -75.3%
Liabilities and Equity 21.1M USD -72.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.09M USD +59.4%
Net Cash Provided by (Used in) Financing Activities -815K USD
Net Cash Provided by (Used in) Investing Activities 14.1M USD -14.6%
Common Stock, Shares Authorized 490M shares 0%
Common Stock, Shares, Issued 23.1M shares +0.05%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -7.08M USD -110%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 18.6M USD +6.15%
Deferred Tax Assets, Valuation Allowance 62.4M USD +33.4%
Deferred Tax Assets, Gross 62.8M USD +30.6%
Operating Lease, Liability 411K USD -81.4%
Payments to Acquire Property, Plant, and Equipment 144K USD -83.6%
Lessee, Operating Lease, Liability, to be Paid 417K USD -81.6%
Property, Plant and Equipment, Gross 1.38M USD -89.5%
Operating Lease, Liability, Current 411K USD -77.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year One 104K USD -90.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6K USD -90.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.6M USD +64%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Additional Paid in Capital 280M USD +0.79%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 792K USD -69.5%
Share-based Payment Arrangement, Expense 2.2M USD -47.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%